Thursday, 12 December 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 12 December 2024
News

Fifth time lucky for J&J?

Posted 9 December 2024 AM

There are high hopes that the PBAC will finally recommend Johnson & Johnson Innovative Medicine's nasal spray Spravato at its last meeting for 2024.

The esketamine-containing medicine for treatment-resistant depression (TRD) has been scheduled for the reimbursement committee's December intracycle meeting being held this Friday.

To see the whole article, please login

Popular

Why pharma redundancies hurt
Supply trouble for in demand drugs
Socials shaping doctor prescribing
Fifth time lucky for J&J?
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home